GLP-1s and Blood Pressure: What the Trials Found

When a drug class is mostly discussed for weight and blood sugar, its other effects can get lost. Blood pressure is one of those quieter findings with GLP-1 receptor agonists, and it turns out to be one of the more consistent. The interesting questions are how large the effect is and how much of it is simply downstream of weight loss.

A healthcare provider checks a patient’s blood pressure with a cuff and stethoscope during a clinic visit

What the data shows

Across the large trials of semaglutide and tirzepatide, systolic blood pressure falls modestly but consistently. Two analyses make the size concrete.

An individual patient data meta-analysis of the STEP 1, 3, and 4 semaglutide trials, published in the European Heart Journal in 2024 and pooling 3,136 participants, found systolic pressure fell by about −4.95 mmHg versus placebo (95% CI −5.86 to −4.05). For tirzepatide, a 2024 analysis of the SURMOUNT-1 obesity trial (2,539 participants) published in Heart reported a pooled systolic reduction of −6.8 mmHg and a diastolic reduction of −4.2 mmHg at 72 weeks.

Analysis	Agent	Systolic change vs placebo	Diastolic
EHJ 2024 (STEP 1/3/4)	Semaglutide	−4.95 mmHg	not separately reported
Heart 2024 (SURMOUNT-1)	Tirzepatide	−6.8 mmHg (pooled)	−4.2 mmHg (pooled)

That sounds minor, and at the individual level it often is. At the population level, a consistent few-point shift in systolic pressure is the kind of change that nudges cardiovascular event rates.

The blood-pressure effect is real and reproducible, but it is modest. These are weight and glucose drugs that happen to help pressure, not antihypertensives.

A woman practices yoga as part of a healthy lifestyle routine that supports weight management and blood pressure control

Weight loss, or something more?

Two explanations are on the table, and they are not mutually exclusive — and the trials let us put rough numbers on the split.

Indirect, via weight. Losing a meaningful amount of body weight reliably lowers blood pressure on its own. The semaglutide meta-analysis estimated that body weight mediated about 89% of the systolic reduction. The tirzepatide analysis put weight’s share lower, at roughly 68% of the systolic and 71% of the diastolic effect.
Direct effects. That leaves an estimated ~11% (semaglutide) to ~32% (tirzepatide) not explained by weight, consistent with plausible direct contributions on sodium handling and the vasculature. The evidence here is suggestive rather than settled, and the two estimates don’t agree closely.

The most honest reading is that weight loss does most of the work, with a probable direct component layered on top whose exact size the trials disagree on. They were not primarily designed to disentangle the two.

A red heart-health icon on a medical background, symbolizing the cardiovascular focus of weight and blood pressure management

Why it matters clinically

For someone with obesity and hypertension, a drug that addresses weight, glucose, and pressure together is an attractive package. It can sometimes allow other medications to be reduced, though that is a decision for a prescriber watching the numbers, not a guarantee. It also feeds the larger cardiometabolic story: the blood-pressure improvement is one of several effects that, together, underpin the cardiovascular outcome benefits seen in dedicated trials.

The takeaway

GLP-1 medications produce a small but dependable drop in blood pressure — on the order of 5 mmHg systolic for semaglutide and around 7 mmHg for tirzepatide in these analyses — mostly tracking weight loss with a likely direct contribution on top. The bottom line is to keep the framing proportionate. This is a welcome bonus that strengthens the overall cardiometabolic case, not a reason to start one of these drugs for hypertension alone.